Please assess the completion status of the following clinical trial:

Trial Title: A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* borderline blood pressure (120-145/80-90 mm Hg);~* borderline or abnormal small artery elasticity (C2) as measured by pulse contour analysis;~* treatment-naive for all blood pressure medications including diuretics for at least 30 days prior to baseline visit;~* able to walk on a treadmill for 3 minutes;~* female patients with reproductive potential must use an approved contraceptive method if appropriate (for example, intrauterine device \[IUD\], birth control pills, or barrier device during and for 1 month after the last dose of study drug;~* voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.~Exclusion Criteria:~* history of intolerance to beta-blockers or clear contraindications to their use; current pharmaceutical treatment of blood pressure;~* known history of cardiovascular disease (myocardial infarction, coronary artery bypass graft, unstable angina, uncontrolled arrhythmias, stroke, etc.);~* known history of diabetes; known history of hepatic, renal or gastrointestinal disorder;~* known history of any illness that may cause additional risk (as determined by study investigator);~* pregnant or lactating women \[when used during pregnancy, beta-blockers may cause fetal harm\];~* participation in a concomitant clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Nebivolol (Type: ACTIVE_COMPARATOR): 5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
- Atenolol (Type: ACTIVE_COMPARATOR): 25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
- Placebo (Type: PLACEBO_COMPARATOR): Continue for 1 month; dose titration to high dose placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur.

Based on this trial design, predict the completion outcome and termination type (if applicable).